中国新药杂志

炎症性肠病治疗的新选择：肠道选择性整合素抑制剂维得利珠单抗

PDF下载

李慧博 ¹^,² , 刘芳 ¹^,² , 翟所迪 ¹^,²

中国新药杂志 | 新药述评与论坛 2021,30(20): 1841-1845

收起

中国新药杂志 |新药述评与论坛 2021 , 30 (20) : 1841 -1845

炎症性肠病治疗的新选择：肠道选择性整合素抑制剂维得利珠单抗

全屏

李慧博¹^,², 刘芳¹^,², 翟所迪¹^,²

作者信息

¹北京大学第三医院药剂科，北京　100191

²北京大学医学部药物评价中心，北京　100191

通讯作者:

翟所迪，男，主任药师，教授，主要从事循证药物评价研究。联系电话：（010）82266686，E-mail：zhaisuodi@163.com。

作者简介:

李慧博，女，硕士，主要从事临床药物治疗、循证药物评价和治疗药物监测工作。联系电话：（010）82265740，E-mail：lihuibo@bjmu.edu.cn。

A new treatment option of inflammatory bowel disease: gut selective integrin inhibitor-vedolizumab

Hui-bo LI¹^,², Fang LIU¹^,², Suo-di ZHAI¹^,²

Affiliations

¹Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China

²Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China

出版时间: 2021-10-30

文章导航

摘要

收起

随着新型生物制剂作为治疗中/重度溃疡性结肠炎和克罗恩病更有效药物的出现，掌握其药理学作用机制、药动学参数以及临床疗效、安全性和经济性特征，对于炎症性肠病（inflammatory bowel disease，IBD）治疗的选择至关重要。维得利珠单抗（vedolizumab）作为一种新型肠道选择性单克隆抗体药物，可特异性结合α₄β₇整合素，阻止炎症细胞迁移到肠道，抑制肠道炎症反应，有较好的临床疗效和安全性。本文对新型生物制剂治疗IBD的作用机制、药动学、临床疗效、安全性和经济性进行综述，以期为临床应用提供参考。

关键词

炎症性肠病 / 维得利珠单抗 / 作用机制 / 药动学/药效学 / 临床疗效 / 安全性

Abstract

收起

With the emergence of new biological agents as more effective drugs for the treatment of ulcerative colitis and Crohn's disease, it is critical to understand their mechanisms, pharmacological characteristics and related clinical efficacy, safety and economic characteristics for the optimal treatment of inflammatory bowel disease (IBP). Vedolizumab is a new type of gut-selective monoclonal antibody that can specifically bind to α₄β₇ integrin, prevent inflammatory cells from migrating to the intestine, inhibit intestinal inflammation, and has demonstrated satisfactory clinical efficacy and safety profiles. This article reviewed the mechanisms of action, pharmacokinetic/pharmacodynamic characteristics, clinical efficacy, safety and economy of vedolizumab, in order to provide guidance for clinical practice.

Key words

inflammatory bowel disease / vedolizumab / pharmacology / pharmacokinetics/pharmacodynamics / clinical efficacy / safety

引用本文

李慧博, 刘芳, 翟所迪. 炎症性肠病治疗的新选择：肠道选择性整合素抑制剂维得利珠单抗. 中国新药杂志, 2021 , 30 (20) : 1841 -1845 .

Hui-bo LI, Fang LIU, Suo-di ZHAI. A new treatment option of inflammatory bowel disease: gut selective integrin inhibitor-vedolizumab[J]. Chinese Journal of New Drugs, 2021 , 30 (20) : 1841 -1845 .

基金

收起

国家“重大新药创制”科技重大专项资助项目(2018ZX09201016)
消化系统炎性疾病新药临床评价技术平台建设

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

GRAHAM DB, XAVIER RJ. From genetics of inflammatory bowel disease towards mechanistic insights[J]. Trends Immunol, 2013, 34(8): 371-378.

[2]

HANAUER SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities[J]. Inflamm Bowel Dis, 2006, 12(Suppl 1): S3-S9.

[3]

WALLACE KL, ZHENG LB, KANAZAWA Y, et al. Immunopathology of inflammatory bowel disease[J]. World J Gastroenterol, 2014, 20(1): 6-21.

[4]

PEYRIN-BIROULET L, CIEZA A, SANDBORN WJ, et al. International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health[J]. Gut, 2012, 61(2): 241-247.

[5]

COSKUN M, STEENHOLDT C, DE BOER NK, et al. Pharmacology and optimization of thiopurines and methotrexate in inflammatory bowel disease[J]. Clin Pharmacokinet, 2016, 55(3): 257-274.

[6]

PARK SC, JEEN YT. Anti-integrin therapy for inflammatory bowel disease[J]. World J Gastroenterol, 2018, 24(17): 1868-1880.

[7]

ORLANDO A, ARMUZZI A, PAPI C, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease[J]. Dig Liver Dis, 2011, 43(1): 1-20.

[8]

FORD AC, SANDBORN WJ, KHAN KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis[J]. Am J Gastroenterol, 2011, 106(4): 644-659.

[9]

FEAGAN BG, LÉMANN M, BEFRITS R, et al. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report[J]. Inflamm Bowel Dis, 2012, 18(1): 152-160.

[10]

SCRIBANO ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence[J]. World J Gastroenterol, 2018, 24(23): 2457-2467.

[11]

MCLEAN LP, SHEA-DONOHUE T, CROSS RK. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease[J]. Immunotherapy, 2012, 4(9): 883-898.

[12]

PEYRIN-BIROULET L, LÉMANN M. Review article: remission rates achievable by current therapies for inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2011, 33(8): 870-879.

[13]

GISBERT JP, MARÍN AC, MCNICHOLL AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed[J]. Aliment Pharmacol Ther, 2015, 41(7): 613-623.

[14]

AKOBENG AA, SANDBORN WJ, BICKSTON SJ, et al. Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us?[J]. Inflamm Bowel Dis, 2014, 20(11): 2132-2141.

[15]

HANAUER SB. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies[J]. Rev Gastroenterol Disord, 2004, 4(Suppl 3): S18-S24.

[16]

LEMAITRE M, KIRCHGESNER J, RUDNICHI A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease[J]. JAMA, 2017, 318(17): 1679-1686.

[17]

FIORINO G, CORREALE C, FRIES W, et al. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease[J]. Expert Rev Clin Immunol, 2010, 6(4): 567-572.

[18]

Entyvio^® (vedolizumab) Approved in Japan for the Treatment of Patients with Moderately to Severely Active Crohn's Disease[EB/OL]. (2020-06-01) [2020-03-25]. https://www.takeda.com/newsroom/newsreleases/2019/entyvio-vedolizumab-approved-in-japan-for-the-treatment-of-patients-with-moderately-to-severely-active-crohns-disease/.

[19]

Entyvio (vedolizumab). Summary of product characteristics (SmPC)[EB/OL]. (2021-01-13) [2021-10-28]. https://www.ema.europa.eu/en/documents/product-information/entyvio-epar-product-information_en.pdf.

[20]

WYANT T, FEDYK E, ABHYANKAR B. An Overview of the mechanism of action of the monoclonal antibody vedolizumab[J]. J Crohns Colitis, 2016, 10(12): 1437-1444.

[21]

BATTAT R, MA C, JAIRATH V, et al. Benefit-risk assessment of vedolizumab in the treatment of Crohn's disease and ulcerative colitis[J]. Drug Saf, 2019, 42(5): 617-632.

[22]

Remicade (infliximab). Summary of product characteristics (SmPC)[EB/OL]. (2020-11-12) [2020-03-25]. https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf.

[23]

Humira (adalimumab). Summary of product characteristics (SmPC)[EB/OL]. (2021-01-29) [2020-03-25]. https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf.

[24]

Simponi (golimumab). Summary of product characteristics (SmPC)[EB/OL]. (2020-11-11) [2020-03-25]. https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf.

[25]

Stelara (ustekinumab). Summary of product characteristics (SmPC)[EB/OL]. (2021-01-13) [2020-03-25]. https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf.

[26]

ROSARIO M, DIRKS NL, MILCH C, et al. A Review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab[J]. Clin Pharmacokinet, 2017, 56(11): 1287-1301.

[27]

ROSARIO M, DIRKS NL, GASTONGUAY MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease[J]. Aliment Pharmacol Ther, 2015, 42(2): 188-202.

[28]

POUILLON L, VERMEIRE S, BOSSUYT P. Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview[J]. BMC Med, 2019, 17(1): 89.

[29]

WILLIET N, BOSCHETTI G, FOVET M, et al. Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months[J]. Clin Gastroenterol Hepatol, 2017, 15(11): 1750-1757.

[30]

FEAGAN BG, RUTGEERTS P, SANDS BE, et al. GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med, 2013, 369(8): 699-710.

[31]

LOFTUS EV, COLOMBEL JF, FEAGAN BG, et al. Long-term efficacy of vedolizumab for ulcerative colitis[J]. J Crohns Colitis, 2017, 11: 400-411.

[32]

SANDS BE, PEYRIN-BIROULET L, LOFTUS EV JR, et al. VARSITY Study Group. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis[J]. N Engl J Med, 2019, 381(13): 1215-1226.

[33]

JAIRATH V, CHAN K, LASCH K, et al. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(6): 711-722.

[34]

SANDBORN WJ, FEAGAN BG, RUTGEERTS P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease[J]. N Engl J Med, 2013, 369(8): 711-721.

[35]

SANDS BE, FEAGAN BG, RUTGEERTS P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed[J]. Gastroenterology, 2014, 147(3): 618-627.

[36]

SANDS BE, SANDBORN WJ, VAN ASSCHE G, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease in patients naïve to or who have failed tumor necrosis factor antagonist therapy[J]. Inflamm Bowel Dis, 2017, 23(1): 97-106.

[37]

VERMEIRE S, LOFTUS EV, COLOMBEL JF, et al. Long-term efficacy of vedolizumab for Crohn's disease[J]. J Crohns Colitis, 2017, 11(4): 412-424.

[38]

DANESE S, SANDBORN WJ, COLOMBEL JF, et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn's disease[J]. Gastroenterology, 2019, 157(4): 1007-1018.

[39]

SINGH S. Network meta-analysis to inform positioning of biologics in patients with Crohn's disease: Promise and perils[J]. Best Pract Res Clin Gastroenterol, 2019, 38-39: 101614.

[40]

COLOMBEL JF, SANDS BE, RUTGEERTS P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease[J]. Gut, 2017, 66(5): 839-851.

[41]

LUKIN D, WEISS A, ANIWAN S, et al. DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor-antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis[J]. J Crohns Colitis, 2018, 12(Suppl 1): S036.

[42]

VAN DEN BERGHE N, VERSTOCKT B, TOPS S, et al. Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients[J]. J Gastroenterol Hepatol, 2019, 34(7): 1175-1181.

[43]

HARBORD M, ELIAKIM R, BETTENWORTH D, et al. European Crohn's and Colitis Organisation[ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative Colitis. Part 2: current management[J]. J Crohns Colitis, 2017, 11(7): 769-784.

[44]

GOMOLLÓN F, DIGNASS A, ANNESE V, et al. ECCO. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016. Part 1: diagnosis and medical management[J]. J Crohns Colitis, 2017, 11(1): 3-25.

[45]

RUBIN DT, ANANTHAKRISHNAN AN, SIEGEL CA, et al. ACG clinical guideline: ulcerative colitis in adults[J]. Am J Gastroenterol, 2019, 114(3): 384-413.

[46]

LICHTENSTEIN GR, LOFTUS EV, ISAACS KL, et al. ACG clinical guideline: management of Crohn's disease in adults[J]. Am J Gastroenterol, 2018, 113(4): 481-517.

[47]

FEUERSTEIN JD, ISAACS KL, SCHNEIDER Y, et al. American Gastroenterological Association Institute Clinical Guidelines Committee[J]. Gastroenterol, 2020(20): 30018-4. doi: 10.1053/j.gastro.2020.01.006.

[48]

SHENG YN, MA L, CHEN J, et al. Cost utility analysis of vedolizumab versus conventional therapy for biologic-naïve, moderately to severely active Crohn's disease patients in China[J]. Value Heal, 2020, 23: 5534.

[49]

SHENG YN, MA L, CHEN J, et al. Cost-effectiveness comparison of vedolizumab, infliximab and conventional therapy for the treatment of biologic-naïve, moderately-to-severely active ulcerative colitis patients in China[J]. Value Heal, 2020, 23: S534.

[50]

朱明明, 冉志华. 以控制白细胞迁移通路为靶点的生物制剂和小分子物质治疗炎症性肠病: 从基础到临床[J]. 中华炎性肠病杂志, 2020, 4(1): 20-24.

2021年第30卷第20期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-30
出版时间：2021-10-30

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2021-01-25

基金

国家“重大新药创制”科技重大专项资助项目(2018ZX09201016)

消化系统炎性疾病新药临床评价技术平台建设

作者信息

¹北京大学第三医院药剂科，北京　100191

²北京大学医学部药物评价中心，北京　100191

通讯作者:

翟所迪，男，主任药师，教授，主要从事循证药物评价研究。联系电话：（010）82266686，E-mail：zhaisuodi@163.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322906856724766916

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT